Table 2.
300-mg Dose Group | Rate Reduction |
---|---|
Cancer mortality | 51% (p = 0.0009) |
Lung cancer incidence | 67% (p < 0.0001) |
Lung cancer mortality | 77% (p = 0.0002) |
300-mg Dose Group | Rate Reduction |
---|---|
Cancer mortality | 51% (p = 0.0009) |
Lung cancer incidence | 67% (p < 0.0001) |
Lung cancer mortality | 77% (p = 0.0002) |